Stryker Co. (NYSE:SYK) Stock Position Increased by Fisher Asset Management LLC

Fisher Asset Management LLC lifted its holdings in Stryker Co. (NYSE:SYK) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,042,317 shares of the medical technology company’s stock after buying an additional 103,326 shares during the period. Fisher Asset Management LLC owned about 1.06% of Stryker worth $1,210,512,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Farmers & Merchants Trust Co of Chambersburg PA lifted its position in shares of Stryker by 203.3% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 61 shares during the last quarter. Rogco LP acquired a new position in Stryker during the 4th quarter valued at $30,000. HBC Financial Services PLLC acquired a new stake in Stryker in the 4th quarter worth $37,000. Bourgeon Capital Management LLC bought a new position in shares of Stryker during the 4th quarter worth about $37,000. Finally, Venturi Wealth Management LLC raised its position in shares of Stryker by 97.1% during the fourth quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock valued at $41,000 after buying an additional 67 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Down 1.0 %

Shares of NYSE:SYK traded down $3.12 during mid-day trading on Thursday, reaching $325.00. 672,113 shares of the stock were exchanged, compared to its average volume of 1,310,056. The stock’s 50 day simple moving average is $348.05 and its 200-day simple moving average is $316.78. Stryker Co. has a one year low of $249.98 and a one year high of $361.41. The company has a market cap of $123.65 billion, a P/E ratio of 37.46, a P/E/G ratio of 2.71 and a beta of 0.91. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.14. The company had revenue of $5.24 billion during the quarter, compared to analysts’ expectations of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.44%. The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the business earned $2.14 EPS. As a group, equities research analysts predict that Stryker Co. will post 11.86 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were given a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date was Wednesday, March 27th. Stryker’s dividend payout ratio is currently 36.53%.

Insider Buying and Selling

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares of the company’s stock, valued at $4,856,522. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 212,109 shares of company stock worth $72,845,768. Corporate insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on SYK shares. BTIG Research boosted their price target on Stryker from $366.00 to $369.00 and gave the company a “buy” rating in a research note on Wednesday. Evercore ISI lifted their price target on shares of Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Roth Mkm lifted their target price on shares of Stryker from $348.00 to $405.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and increased their price target for the stock from $315.00 to $360.00 in a research report on Wednesday, January 31st. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $357.05.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.